Biological binding molecules
The invention relates to the field of the preparation, identification and selection of biological binding molecules such as antibodies or fragments thereof, and also the use thereof in the context of therapy and prophylaxis of cancers, such as malignant B-cell neoplasia in particular. The binding molecules are capable of selectively binding to B-cell receptors that have a light chain according to SEQ ID NO. 18.
1 . A biological binding molecule which selectively binds to B cell receptors, characterized by the presence of a light chain having a sequence according to SEQ ID No. 18, but not to B-cell receptors lacking a light chain according to SEQ ID No. 18, wherein the biological binding molecule is an antibody or a functional fragment thereof having an antigen-binding site, and wherein the biological binding molecule comprises variable parts of a heavy chain corresponding to CDR1, CDR2 and CDR3 given respectively in SEQ ID NO(s). 19, 20 and 21 and variable parts of a light chain corresponding to CDR1, CDR2 and CDR3 given respectively in SEQ ID NO(s). 22, 23 and 24.
2 . The biological binding molecule according to claim 1 , characterized in that it is in the form of a fusion protein with T-cell specific activation domains.
3 . The biological binding molecule according to claim 1 , characterized in that it comprises at least one additional region for isolating or killing B-cell neoplasia.
4 . A composition of substances comprising a biological binding molecule according to claim 1 for therapeutic purposes.
5 . The composition of substances according to claim 4 , characterized in that it additionally comprises an antibody or a functional fragment thereof against the light or heavy chain of the B-cell receptor or against the light and heavy chain of the B-cell receptor.
6 . The composition of substances according to claim 4 , characterized in that the binding molecule is in the form of a fusion protein with T-cell specific activation domains.
7 . The composition of substances according to claim 4 , characterized in that the binding molecule comprises at least one additional region for isolating or killing B-cell neoplasia.
8 . A method of therapy comprising administering to a subject a therapeutically effective quantity of the biological binding molecule according to claim 1 .
9 . The method of claim 8 for therapy of B-cell malignant neoplasia.